阿替普酶联合依达拉奉治疗急性脑梗死的临床疗效观察
|
摘要
目的探讨阿替普酶联合依达拉奉治疗急性脑梗死的临床疗效。方法选取2014年6月—2018年6月我院收治的50例急性脑梗死患者作为研究对象,按患者入院顺序,将其分为研究组和对照组。对照组(27例)给予阿替普酶治疗,研究组(23例)在以上基础上联合使用依达拉奉,对比两组患者的临床疗效。结果两组治疗前NIHSS评分对比,差异无统计学意义(P> 0.05);研究组治疗后NIHSS评分低于对照组,差异具有统计学意义(P <0.05);研究组患者的治疗总有效率高于对照组,差异具有统计学意义(P <0.05);研究组各项QOL评分高于对照组,差异具有统计学意义(P <0.05)。结论在ACI治疗中应用阿替普酶联合依达拉奉可恢复患者神经功能缺损,提高临床治疗效果,改善患者生活质量。
Objective To explore the clinical effect of alteplase combined with idaravone in the treatment of acute cerebral infarction. Methods A total of 50 atients with acute cerebral infarction admitted to our hospital from June 2014 to June 2018 were selected as the study subjects. According to the order of admission, the patients were divided into study group and control group. The control group(27 cases) was treated with alteplase. The study group(23 cases) used edaravone on the basis of the above. The clinical effects of the two groups were compared. Results There was no significant difference in NIHSS score between the two groups before treatment(P > 0.05). After treatment, the NIHSS score of the study group was lower than that of the control group, and the difference was statistically significant(P < 0.05). The total effective rate of the study group was higher than that of the control group, with statistical significance(P < 0.05); the QOL scores of the study group were higher than those of the control group, with statistical significance(P < 0.05). Conclusion Atyplase combined with edaravone in the treatment of ACI can restore the neurological deficits of patients, improve the clinical efficacy and improve the quality of life of patients.
Objective To explore the clinical effect of alteplase combined with idaravone in the treatment of acute cerebral infarction. Methods A total of 50 atients with acute cerebral infarction admitted to our hospital from June 2014 to June 2018 were selected as the study subjects. According to the order of admission, the patients were divided into study group and control group. The control group(27 cases) was treated with alteplase. The study group(23 cases) used edaravone on the basis of the above. The clinical effects of the two groups were compared. Results There was no significant difference in NIHSS score between the two groups before treatment(P > 0.05). After treatment, the NIHSS score of the study group was lower than that of the control group, and the difference was statistically significant(P < 0.05). The total effective rate of the study group was higher than that of the control group, with statistical significance(P < 0.05); the QOL scores of the study group were higher than those of the control group, with statistical significance(P < 0.05). Conclusion Atyplase combined with edaravone in the treatment of ACI can restore the neurological deficits of patients, improve the clinical efficacy and improve the quality of life of patients.
引文
[1]宜海杰,韩秀平,白利杰,等.依达拉奉联合阿替普酶对急性脑梗死炎性因子的影响[J].现代生物医学进展,2016,16(36):7143-7146.
[2]冯琼,涂明义,黄娟,等.丁苯酞联合阿替普酶治疗急性脑梗死的疗效观察[J].现代药物与临床,2017,32(10):1876-1880.
[3]王大力,赵晓晶,张江,等.急性生理学及慢性健康状况评分Ⅱ和美国国立卫生研究院卒中量表评分对急性脑梗死患者预后评估的价值[J].临床神经病学杂志,2009,22(4):251-253.
[4]中华人民共和国卫生部.新药(西药)临床前研究指导原则汇编[M].中华人民共和国卫生部药政局,1993:57-58。
[5]曹卫华,李俊,郭春晖.脑卒中患者的生活质量评价量表及其运用[J].中国慢性病预防与控制,2003,11(3):140-142.
[6]曹喜贵,何赵娜.消栓肠溶胶囊联合阿替普酶治疗急性脑梗死的临床研究[J].现代药物与临床,2018,33(4):740-744.
[7]王静,张爱香,张璐璐,等.依达拉奉联合疏血通对急性脑梗死患者的临床疗效及机制研究[J].现代生物医学进展,2016,16(25):4883-4885,4912.
[8]杨成.银杏达莫联合依达拉奉治疗急性脑梗死的临床疗效观察[J].实用心脑肺血管病杂志,2016,24(4):97-99.
[9]陈庆友,张艳蕉,于熙莹.丁苯酞联合依达拉奉治疗急性脑梗死的临床研究[J].中国临床药理学杂志,2016,32(16):1453-1455.
[10]宋爱晶,李野,于浩光.前列地尔联合阿替普酶治疗急性脑梗死的疗效观察[J].现代药物与临床,2016,31(6):801-804.
[11]郝军,陈欣,吴海琴.丹红注射液联合阿替普酶治疗不同分型急性脑梗死的疗效观察[J].现代药物与临床,2016,31(9):1347-1353.
[12]黄松.阿替普酶联合丁苯酞对脑梗死的疗效和炎性因子的影响[J].基因组学与应用生物学,2017,36(1):18-22.
[2]冯琼,涂明义,黄娟,等.丁苯酞联合阿替普酶治疗急性脑梗死的疗效观察[J].现代药物与临床,2017,32(10):1876-1880.
[3]王大力,赵晓晶,张江,等.急性生理学及慢性健康状况评分Ⅱ和美国国立卫生研究院卒中量表评分对急性脑梗死患者预后评估的价值[J].临床神经病学杂志,2009,22(4):251-253.
[4]中华人民共和国卫生部.新药(西药)临床前研究指导原则汇编[M].中华人民共和国卫生部药政局,1993:57-58。
[5]曹卫华,李俊,郭春晖.脑卒中患者的生活质量评价量表及其运用[J].中国慢性病预防与控制,2003,11(3):140-142.
[6]曹喜贵,何赵娜.消栓肠溶胶囊联合阿替普酶治疗急性脑梗死的临床研究[J].现代药物与临床,2018,33(4):740-744.
[7]王静,张爱香,张璐璐,等.依达拉奉联合疏血通对急性脑梗死患者的临床疗效及机制研究[J].现代生物医学进展,2016,16(25):4883-4885,4912.
[8]杨成.银杏达莫联合依达拉奉治疗急性脑梗死的临床疗效观察[J].实用心脑肺血管病杂志,2016,24(4):97-99.
[9]陈庆友,张艳蕉,于熙莹.丁苯酞联合依达拉奉治疗急性脑梗死的临床研究[J].中国临床药理学杂志,2016,32(16):1453-1455.
[10]宋爱晶,李野,于浩光.前列地尔联合阿替普酶治疗急性脑梗死的疗效观察[J].现代药物与临床,2016,31(6):801-804.
[11]郝军,陈欣,吴海琴.丹红注射液联合阿替普酶治疗不同分型急性脑梗死的疗效观察[J].现代药物与临床,2016,31(9):1347-1353.
[12]黄松.阿替普酶联合丁苯酞对脑梗死的疗效和炎性因子的影响[J].基因组学与应用生物学,2017,36(1):18-22.